# Pharmacogenomics for Improving Pediatric ADHD Treatment

> **NCT03730870** · NA · TERMINATED · sponsor: **Clinical and Translational Genome Research Institute, Inc.** · enrollment: 21 (actual)

## Conditions studied

- Attention Deficit Disorders With Hyperactivity

## Interventions

- **DIAGNOSTIC_TEST:** Pharmacogenomics report

## Key facts

- **NCT ID:** NCT03730870
- **Lead sponsor:** Clinical and Translational Genome Research Institute, Inc.
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-28
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-02-28
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** This study's genetic testing laboratory has suspended operations pending discussions with the FDA concerning clinical interpretation of pharmacogenomics tests.
- **Last updated:** 2020-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03730870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03730870, "Pharmacogenomics for Improving Pediatric ADHD Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03730870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*